Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
| Title: | Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. |
|---|---|
| Authors: | Karacin C; Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. cengizkaracin@yahoo.com.; Oksuzoglu B; Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.; Demirci A; Department of Medical Oncology, Sakarya University, Sakarya, Turkey.; Keskinkılıç M; Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey.; Baytemür NK; Department of Medical Oncology, Memorial Hospital, Ankara, Turkey.; Yılmaz F; Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.; Selvi O; Department of Medical Oncology, Okmeydanı Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.; Erdem D; Department of Medical Oncology, VM Medical Park Hospital, Samsun, Turkey.; Avşar E; Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey.; Paksoy N; Department of Medical Oncology, Istanbul University Instıtue of Oncology, Istanbul, Turkey.; Demir N; Department of Medical Oncology, Acıbadem Hospital, Kayseri, Turkey.; Göksu SS; Department of Medical Oncology, Akdeniz University, Antalya, Turkey.; Türker S; Department of Medical Oncology, Zonguldak Hospital, Zonguldak, Turkey.; Bayram E; Department of Medical Oncology, Çukurova University, Adana, Turkey.; Çelebi A; Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.; Yılmaz H; Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey.; Kuzu ÖF; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.; Kahraman S; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.; Gökmen İ; Department of Medical Oncology, Trakya University, Edirne, Turkey.; Sakin A; Department of Medical Oncology, Istanbul Medipol University Bahçelievler Hospital, Istanbul, Turkey.; Alkan A; Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey.; Nayır E; Mersin Medical Park Hospital, Department of Medical Oncology, Mersin, Turkey.; Uğraklı M; Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey.; Acar Ö; Department of Medical Oncology, Celal Bayar University, Manisa, Turkey.; Ertürk İ; Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey.; Demir H; Department of Medical Oncology, Afyonkarahisar Health Sciences University Hospital, Afyonkarahisar, Turkey.; Aslan F; Department of Medical Oncology, Ankara Medical Park Hospital, Ankara, Turkey.; Sönmez Ö; Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey.; Korkmaz T; Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey.; Celayir ÖM; Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey.; Karadağ İ; Department of Medical Oncology, Hitit University Hospital, Çorum, Turkey.; Kayıkçıoğlu E; Department of Medical Oncology, Süleyman Demirel University Hospital, Isparta, Turkey.; Şakalar T; Department of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, Turkey.; Öktem İN; Department of Medical Oncology, Ersin Arslan Training and Research Hospital, Gaziantep, Turkey.; Eren T; Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.; Erul E; Department of Medical Oncology, Hacettepe University Instıtue of Oncology, Ankara, Turkey.; Mocan EE; Department of Medical Oncology, Ankara University, Ankara, Turkey.; Kalkan Z; Department of Medical Oncology, Dicle University, Diyarbakır, Turkey.; Yıldırım N; Department of Medical Oncology, Fırat University, Elazığ, Turkey.; Ergün Y; Batman Training and Research Hospital, Batman, Turkey.; Akagündüz B; Department of Medical Oncology, Erzincan Binali Yıldırım University, Erzincan, Turkey.; Karakaya S; Department of Medical Oncology, Atatürk Pulmonary Diseases Hospital, Ankara, Turkey.; Kut E; Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey.; Teker F; Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey.; Demirel BÇ; Department of Medical Oncology, Pamukkale University, Denizli, Turkey.; Karaboyun K; Department of Medical Oncology, Namık Kemal University, Tekirdağ, Turkey.; Almuradova E; Department of Medical Oncology, Ege University, İzmir, Turkey.; Ünal OÜ; UHS İzmir Tepecik Training and Research Hospital, İzmir, Turkey.; Oyman A; Department of Medical Oncology, Ümraniye Training and Research Hospital, Istanbul, Turkey.; Işık D; Kocaeli Medical Park, Department of Medical Oncology, Kocaeli, Turkey.; Okutur K; Department of Medical Oncology, Bahçelievler Memorial Hospital, Istanbul, Turkey.; Öztosun B; Department of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey.; Gülbağcı BB; Department of Medical Oncology, Sakarya University, Sakarya, Turkey.; Kalender ME; Department of Medical Oncology, Meddem Hospital, Isparta, Turkey.; Şahin E; Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey.; Seyyar M; Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey.; Özdemir Ö; İzmir Bozyaka Training and Research Hospital, İzmir, Turkey.; Selçukbiricik F; Department of Medical Oncology, Koç University, Istanbul, Turkey.; Kanıtez M; Department of Medical Oncology, American Hospital, Istanbul, Turkey.; Dede İ; Department of Medical Oncology, Mustafa Kemal University, Hatay, Turkey.; Gümüş M; Department of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey.; Gökmen E; Department of Medical Oncology, Ege University, İzmir, Turkey.; Yaren A; Department of Medical Oncology, Pamukkale University, Denizli, Turkey.; Menekşe S; Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey.; Ebinç S; Department of Medical Oncology, Dicle University, Diyarbakır, Turkey.; Aksoy S; Department of Medical Oncology, Hacettepe University Instıtue of Oncology, Ankara, Turkey.; İmamoğlu Gİ; Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.; Altınbaş M; Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.; Çetin B; Department of Medical Oncology, Süleyman Demirel University Hospital, Isparta, Turkey.; Uluç BO; Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey.; Er Ö; Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey.; Karadurmuş N; Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey.; Erdoğan AP; Department of Medical Oncology, Celal Bayar University, Manisa, Turkey.; Artaç M; Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey.; Tanrıverdi Ö; Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey.; Çiçin İ; Department of Medical Oncology, Trakya University, Edirne, Turkey.; Şendur MAN; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.; Oktay E; Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey.; Bayoğlu İV; Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.; Paydaş S; Department of Medical Oncology, Çukurova University, Adana, Turkey.; Aydıner A; Department of Medical Oncology, Istanbul University Instıtue of Oncology, Istanbul, Turkey.; Salim DK; Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey.; Geredeli Ç; Department of Medical Oncology, Okmeydanı Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.; Yavuzşen T; Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey.; Doğan M; Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.; Hacıbekiroğlu İ; Department of Medical Oncology, Sakarya University, Sakarya, Turkey. |
| Source: | BMC cancer [BMC Cancer] 2023 Feb 10; Vol. 23 (1), pp. 136. Date of Electronic Publication: 2023 Feb 10. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BioMed Central, [2001- |
| MeSH Terms: | Breast Neoplasms*; Erb-b2 Receptor Tyrosine Kinases/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Fulvestrant/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Female ; Everolimus ; Disease Progression |
| Abstract: | Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based).; Methods: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy.; Results: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months.; Conclusion: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.; (© 2023. The Author(s).) |
| Comments: | Erratum in: BMC Cancer. 2023 Feb 27;23(1):192. doi: 10.1186/s12885-023-10662-3.. (PMID: 36849943) |
| References: | Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3):218–28. (PMID: 10.1093/jnci/djh02514759989); Gennari A, André F, Barrios C, Cortés J, De Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆. Ann Oncol. 2021;32(12):1475–95. (PMID: 10.1016/j.annonc.2021.09.01934678411); Gradishar WJ. NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer. J Natl Compr Canc Netw. 2022;20(5.5):561–5. (PMID: 10.6004/jnccn.2022.5016); Karacin C, Ergun Y, Oksuzoglu OB. Saying goodbye to primary endocrine resistance for advanced breast cancer? Med Oncol. 2021;38(1):1–2. (PMID: 10.1007/s12032-020-01449-8); Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. (PMID: 10.1056/NEJMoa160970927717303); Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36. (PMID: 10.1056/NEJMoa160730327959613); Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489–98. (PMID: 10.1016/S1470-2045(21)00034-633794206); Princic N, Aizer A, Tang DH, Smith DM, Johnson W, Bardia A. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. Curr Med Res Opin. 2019;35(1):73–80. (PMID: 10.1080/03007995.2018.151950030175631); Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Ohtani S, et al. Analysis of subsequent therapy in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and-3. Breast Cancer. 2021;28(2):335–45. (PMID: 10.1007/s12282-020-01162-433085032); Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, et al. Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Res. 2019;21(1):1–7. (PMID: 10.1186/s13058-019-1149-5); Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, et al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J Natl Compr Canc Netw. 2019;17(2):141–7. (PMID: 10.6004/jnccn.2018.7094307871276752198); Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. (PMID: 10.1056/NEJMoa110965322149876); Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res. 2021;23(1):1–10. (PMID: 10.1186/s13058-021-01394-y); Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG, et al. Outcome of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on palbociclib. Breast Cancer: Basic and Clinical Research. 2020;14:1178223420944864. (PMID: 32753876); Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. Oncologist. 2021;26(2):101–6. (PMID: 10.1002/onco.1360933230905) |
| Contributed Indexing: | Keywords: Advanced breast cancer; Cyclin-dependent kinase; Endocrine treatment; Everolimus; Fulvestrant; Hormonotherapy; Palbociclib; Ribociclib |
| Substance Nomenclature: | 9HW64Q8G6G (Everolimus); EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases); 0 (Protein Kinase Inhibitors); 22X328QOC4 (Fulvestrant) |
| Entry Date(s): | Date Created: 20230211 Date Completed: 20230214 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9912535 |
| DOI: | 10.1186/s12885-023-10609-8 |
| PMID: | 36765293 |
| Database: | MEDLINE |
Journal Article